MSD Ireland is the Irish division of Merck & Co., known as MSD outside the US and Canada. It employs over 2,000 people across five Irish sites and has invested over €2.2 billion in Ireland over five decades. MSD manufactures or packages many of its leading products in Ireland, including 12 of its top 20 global products. It is focused on partnerships with Irish hospitals that support education, patient programs, and disease management. MSD is adapting to changes in the healthcare system by realigning resources and account managers to focus on growth areas like infectious disease and oncology.

1. MSD Ireland
Mick Phelan
Business Unit Director

2.  Known as MSD worldwide except in the US and Canada where we are
Merck
 A global healthcare leader working to help the world be well
 The world’s No. 2 healthcare company that operates in
140 countries
 We develop and deliver prescription medicines, vaccines, biologic
therapies, and consumer care and animal health products
 We are committed to increasing access to healthcare through far-
reaching policies, programmes and partnerships to help people around
the world lead healthier lives
MSD across the Globe

3.  We employ over 2,000 people at sites in Dublin, Carlow, Cork,
Tipperary and Wicklow.
 We have invested over €2.2bn in Ireland over the last five
decades
 In 2011 we spent in excess of €400 million on goods and services
in Ireland, thus supporting many other businesses and jobs in the
Irish economy
 In 2012 we contributed €2.3m in support of medical education for
healthcare professionals, for local Irish charities, community and
patient groups, and in our work towards environmental
sustainability
MSD in Ireland

4. Irish Sites

5.  We manufacture or package many of our leading products for the world market
in Ireland – 12 of our global top 20 products are manufactured in Ireland
 Our Irish sites are renowned for their capability to rapidly introduce new
products (and additional volumes of existing products) at minimal additional
capital cost, ensuring supply for new product launches / expanding market
opportunities
 Our Carlow site is a state-of-the-art vaccines and biologics facility, with
ambitious growth plans for its future. It is MSD’s first vaccines facility to be built
outside of the US
 Our Ballydine site currently supports worldwide revenues of approx. €8bn and
focuses on new product R&D commercialisation
Our Manufacturing Presence

6. Our Areas of Focus

7. MSD Partnership in Hospitals
 Longstanding contributions to Education, Patient Programs,
Disease Management, Clinical Staff Support, Health Care
Technology
 Therapeutic focus include Rheumatology, Gastroenterology,
Cardiology, Diabetes, Microbiology, Critical Care and Surgery
 We are focused on understanding the changing environment:
e.g., emergence of Hospital Groups, MFTP and other planned
Health Care Reforms.
 MSD is evolving to reflect these changes and to ensure that we
remain an effective partner for you through the change.

8. MSD is Evolving
 10% reduction through voluntary redundancies Dec 2013
 Refocusing efforts to growth areas and new product launches
(e.g., Infectious Disease, Oncology)
 Resources increased in Market Access, Account Management
and Medical Affairs
 Account Management aligned with Hospital Group structure

9. Hospital Account Managers
Ger Bowens
Niamh McEvoy
Anne Martina Mulligan
• Interact with Hospital Group Management
• Understand the Group, its priorities and ID mutually beneficial
partnership opportunities
• Commercial Negotiations
• Interact with Hospital Group Management
• Understand the Group, its priorities and ID mutually beneficial
partnership opportunities
• Commercial Negotiations

10. MSD Hospital Group Partnership Approach
Partnership opportunities close to our current and pipeline therapeutic areas
Opportunities may be MSD alone or in collaboration with other pharmacy/industry
partners
Focus, at least initially on smaller, short term, patient outcome focused and
measurable initiatives
Large partnership groups with broad, long term, difficult to measure objectives are
less attractive.
We are committed to MSD’s ethical and compliance standards and requirements.
When working with industry partners, recognise that compliance requirements will
differ by company
Partnership engagements may identify potential business development opportunities

11. Thank You www.msd.ie